IgA Vasculitis
12
7
8
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
8.3%
1 terminated out of 12 trials
50.0%
-36.5% vs benchmark
33%
4 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (12)
Study of Ravulizumab in Pediatric Participants With Primary IgAN
A Randomized Multicenter Study for Isolated Skin Vasculitis
Vasculitis Pregnancy Registry
VCRC Tissue Repository
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis
Evaluation of Glucocorticoids Plus Rituximab in Patients with Newly-Diagnosed or Relapsing IgA Vasculitis
Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis
Journey of Patients With Vasculitis From First Symptom to Diagnosis